1. Executive Summary
1.1. Global Oncology Drugs Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Key Promotional Strategies, By Manufacturers
2.4. Disease Epidemiology
2.5. Pipeline Assessment
2.6. Regulatory Landscape
2.7. COVID-19 Impact Analysis
2.8. Economic Overview
2.8.1. World Economic Projections
2.9. PESTLE Analysis
3. Global Oncology Drugs Market Outlook, 2019 - 2031
3.1. Global Oncology Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2019 - 2031
3.1.1. Key Highlights
3.1.1.1. Chemotherapy
3.1.1.1.1. Alkylating Agents
3.1.1.1.2. Antimetabolites
3.1.1.1.3. Anti-tumour Antibiotics
3.1.1.1.4. Topoisomerase Inhibitors
3.1.1.1.5. Mitotic Inhibitors
3.1.1.1.6. Others
3.1.1.2. Targeted Therapy
3.1.1.2.1. Monoclonal Antibodies
3.1.1.2.2. Small molecule Inhibitors
3.1.1.3. Immunotherapy
3.1.1.3.1. Immune Checkpoint Inhibitors.
3.1.1.3.2. Cell Therapy and Gene Therapy
3.1.1.3.3. Oncolytic Virus Therapy
3.1.1.3.4. Immune System Modulators
3.1.1.3.5. Others
3.1.1.4. Hormonal Therapy
3.2. Global Oncology Drugs Market Outlook, by Indication, Value (US$ Bn), 2019 - 2031
3.2.1. Key Highlights
3.2.1.1. Breast Cancer
3.2.1.2. Lung Cancer
3.2.1.3. Prostate Cancer
3.2.1.4. Multiple Myeloma
3.2.1.5. Colorectal Cancer
3.2.1.6. Non-Hodgkin's Lymphoma
3.2.1.7. Kidney Cancer
3.2.1.8. Chronic lymphocytic Leukaemia
3.2.1.9. Melanoma
3.2.1.10. Others
3.3. Global Oncology Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2019 - 2031
3.3.1. Key Highlights
3.3.1.1. Oral
3.3.1.2. Injectable
3.4. Global Oncology Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2031
3.4.1. Key Highlights
3.4.1.1. Hospital Pharmacies
3.4.1.2. Retail Pharmacies
3.4.1.3. Others
3.5. Global Oncology Drugs Market Outlook, by Region, Value (US$ Bn), 2019 - 2031
3.5.1. Key Highlights
3.5.1.1. North America
3.5.1.2. Europe
3.5.1.3. Asia Pacific
3.5.1.4. Latin America
3.5.1.5. Middle East & Africa
4. North America Oncology Drugs Market Outlook, 2019 - 2031
4.1. North America Oncology Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2019 - 2031
4.1.1. Key Highlights
4.1.1.1. Chemotherapy
4.1.1.1.1. Alkylating Agents
4.1.1.1.2. Antimetabolites
4.1.1.1.3. Anti-tumour Antibiotics
4.1.1.1.4. Topoisomerase Inhibitors
4.1.1.1.5. Mitotic Inhibitors
4.1.1.1.6. Others
4.1.1.2. Targeted Therapy
4.1.1.2.1. Monoclonal Antibodies
4.1.1.2.2. Small molecule Inhibitors
4.1.1.3. Immunotherapy
4.1.1.3.1. Immune Checkpoint Inhibitors.
4.1.1.3.2. Cell Therapy and Gene Therapy
4.1.1.3.3. Oncolytic Virus Therapy
4.1.1.3.4. Immune System Modulators
4.1.1.3.5. Others
4.1.1.4. Hormonal Therapy
4.2. North America Oncology Drugs Market Outlook, by Indication, Value (US$ Bn), 2019 - 2031
4.2.1. Key Highlights
4.2.1.1. Breast Cancer
4.2.1.2. Lung Cancer
4.2.1.3. Prostate Cancer
4.2.1.4. Multiple Myeloma
4.2.1.5. Colorectal Cancer
4.2.1.6. Non-Hodgkin's Lymphoma
4.2.1.7. Kidney Cancer
4.2.1.8. Chronic lymphocytic Leukaemia
4.2.1.9. Melanoma
4.2.1.10. Others
4.3. North America Oncology Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2019 - 2031
4.3.1. Key Highlights
4.3.1.1. Oral
4.3.1.2. Injectable
4.4. North America Oncology Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2031
4.4.1. Key Highlights
4.4.1.1. Hospital Pharmacies
4.4.1.2. Retail Pharmacies
4.4.1.3. Others
4.4.2. BPS Analysis/Market Attractiveness Analysis
4.5. North America Oncology Drugs Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
4.5.1. Key Highlights
4.5.1.1. U.S. Oncology Drugs Market by Drug Class, Value (US$ Bn), 2019 - 2031
4.5.1.2. U.S. Oncology Drugs Market by Indication, Value (US$ Bn), 2019 - 2031
4.5.1.3. U.S. Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2019 - 2031
4.5.1.4. U.S. Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
4.5.1.5. Canada Oncology Drugs Market by Drug Class, Value (US$ Bn), 2019 - 2031
4.5.1.6. Canada Oncology Drugs Market by Indication, Value (US$ Bn), 2019 - 2031
4.5.1.7. Canada Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2019 - 2031
4.5.1.8. Canada Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
4.5.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Oncology Drugs Market Outlook, 2019 - 2031
5.1. Europe Oncology Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2019 - 2031
5.1.1. Key Highlights
5.1.1.1. Chemotherapy
5.1.1.1.1. Alkylating Agents
5.1.1.1.2. Antimetabolites
5.1.1.1.3. Anti-tumour Antibiotics
5.1.1.1.4. Topoisomerase Inhibitors
5.1.1.1.5. Mitotic Inhibitors
5.1.1.1.6. Others
5.1.1.2. Targeted Therapy
5.1.1.2.1. Monoclonal Antibodies
5.1.1.2.2. Small molecule Inhibitors
5.1.1.3. Immunotherapy
5.1.1.3.1. Immune Checkpoint Inhibitors.
5.1.1.3.2. Cell Therapy and Gene Therapy
5.1.1.3.3. Oncolytic Virus Therapy
5.1.1.3.4. Immune System Modulators
5.1.1.3.5. Others
5.1.1.4. Hormonal Therapy
5.2. Europe Oncology Drugs Market Outlook, by Indication, Value (US$ Bn), 2019 - 2031
5.2.1. Key Highlights
5.2.1.1. Breast Cancer
5.2.1.2. Lung Cancer
5.2.1.3. Prostate Cancer
5.2.1.4. Multiple Myeloma
5.2.1.5. Colorectal Cancer
5.2.1.6. Non-Hodgkin's Lymphoma
5.2.1.7. Kidney Cancer
5.2.1.8. Chronic lymphocytic Leukaemia
5.2.1.9. Melanoma
5.2.1.10. Others
5.3. Europe Oncology Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2019 - 2031
5.3.1. Key Highlights
5.3.1.1. Oral
5.3.1.2. Injectable
5.4. Europe Oncology Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2031
5.4.1. Key Highlights
5.4.1.1. Hospital Pharmacies
5.4.1.2. Retail Pharmacies
5.4.1.3. Others
5.4.2. BPS Analysis/Market Attractiveness Analysis
5.5. Europe Oncology Drugs Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
5.5.1. Key Highlights
5.5.1.1. Germany Oncology Drugs Market by Drug Class, Value (US$ Bn), 2019 - 2031
5.5.1.2. Germany Oncology Drugs Market by Indication, Value (US$ Bn), 2019 - 2031
5.5.1.3. Germany Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2019 - 2031
5.5.1.4. Germany Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
5.5.1.5. U.K. Oncology Drugs Market by Drug Class, Value (US$ Bn), 2019 - 2031
5.5.1.6. U.K. Oncology Drugs Market by Indication, Value (US$ Bn), 2019 - 2031
5.5.1.7. U.K. Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2019 - 2031
5.5.1.8. U.K. Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
5.5.1.9. France Oncology Drugs Market by Drug Class, Value (US$ Bn), 2019 - 2031
5.5.1.10. France Oncology Drugs Market by Indication, Value (US$ Bn), 2019 - 2031
5.5.1.11. France Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2019 - 2031
5.5.1.12. France Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
5.5.1.13. Italy Oncology Drugs Market by Drug Class, Value (US$ Bn), 2019 - 2031
5.5.1.14. Italy Oncology Drugs Market by Indication, Value (US$ Bn), 2019 - 2031
5.5.1.15. Italy Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2019 - 2031
5.5.1.16. Italy Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
5.5.1.17. Turkey Oncology Drugs Market by Drug Class, Value (US$ Bn), 2019 - 2031
5.5.1.18. Turkey Oncology Drugs Market by Indication, Value (US$ Bn), 2019 - 2031
5.5.1.19. Turkey Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2019 - 2031
5.5.1.20. Turkey Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
5.5.1.21. Russia Oncology Drugs Market by Drug Class, Value (US$ Bn), 2019 - 2031
5.5.1.22. Russia Oncology Drugs Market by Indication, Value (US$ Bn), 2019 - 2031
5.5.1.23. Russia Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2019 - 2031
5.5.1.24. Russia Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
5.5.1.25. Rest of Europe Oncology Drugs Market by Drug Class, Value (US$ Bn), 2019 - 2031
5.5.1.26. Rest of Europe Oncology Drugs Market by Indication, Value (US$ Bn), 2019 - 2031
5.5.1.27. Rest of Europe Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2019 - 2031
5.5.1.28. Rest of Europe Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
5.5.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Oncology Drugs Market Outlook, 2019 - 2031
6.1. Asia Pacific Oncology Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2019 - 2031
6.1.1. Key Highlights
6.1.1.1. Chemotherapy
6.1.1.1.1. Alkylating Agents
6.1.1.1.2. Antimetabolites
6.1.1.1.3. Anti-tumour Antibiotics
6.1.1.1.4. Topoisomerase Inhibitors
6.1.1.1.5. Mitotic Inhibitors
6.1.1.1.6. Others
6.1.1.2. Targeted Therapy
6.1.1.2.1. Monoclonal Antibodies
6.1.1.2.2. Small molecule Inhibitors
6.1.1.3. Immunotherapy
6.1.1.3.1. Immune Checkpoint Inhibitors.
6.1.1.3.2. Cell Therapy and Gene Therapy
6.1.1.3.3. Oncolytic Virus Therapy
6.1.1.3.4. Immune System Modulators
6.1.1.3.5. Others
6.1.1.4. Hormonal Therapy
6.2. Asia Pacific Oncology Drugs Market Outlook, by Indication, Value (US$ Bn), 2019 - 2031
6.2.1. Key Highlights
6.2.1.1. Breast Cancer
6.2.1.2. Lung Cancer
6.2.1.3. Prostate Cancer
6.2.1.4. Multiple Myeloma
6.2.1.5. Colorectal Cancer
6.2.1.6. Non-Hodgkin's Lymphoma
6.2.1.7. Kidney Cancer
6.2.1.8. Chronic lymphocytic Leukaemia
6.2.1.9. Melanoma
6.2.1.10. Others
6.3. Asia Pacific Oncology Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2019 - 2031
6.3.1. Key Highlights
6.3.1.1. Oral
6.3.1.2. Injectable
6.4. Asia Pacific Oncology Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2031
6.4.1. Key Highlights
6.4.1.1. Hospital Pharmacies
6.4.1.2. Retail Pharmacies
6.4.1.3. Others
6.4.2. BPS Analysis/Market Attractiveness Analysis
6.5. Asia Pacific Oncology Drugs Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
6.5.1. Key Highlights
6.5.1.1. China Oncology Drugs Market by Drug Class, Value (US$ Bn), 2019 - 2031
6.5.1.2. China Oncology Drugs Market by Indication, Value (US$ Bn), 2019 - 2031
6.5.1.3. China Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2019 - 2031
6.5.1.4. China Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
6.5.1.5. Japan Oncology Drugs Market by Drug Class, Value (US$ Bn), 2019 - 2031
6.5.1.6. Japan Oncology Drugs Market by Indication, Value (US$ Bn), 2019 - 2031
6.5.1.7. Japan Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2019 - 2031
6.5.1.8. Japan Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
6.5.1.9. South Korea Oncology Drugs Market by Drug Class, Value (US$ Bn), 2019 - 2031
6.5.1.10. South Korea Oncology Drugs Market by Indication, Value (US$ Bn), 2019 - 2031
6.5.1.11. South Korea Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2019 - 2031
6.5.1.12. South Korea Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
6.5.1.13. India Oncology Drugs Market by Drug Class, Value (US$ Bn), 2019 - 2031
6.5.1.14. India Oncology Drugs Market by Indication, Value (US$ Bn), 2019 - 2031
6.5.1.15. India Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2019 - 2031
6.5.1.16. India Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
6.5.1.17. Southeast Asia Oncology Drugs Market by Drug Class, Value (US$ Bn), 2019 - 2031
6.5.1.18. Southeast Asia Oncology Drugs Market by Indication, Value (US$ Bn), 2019 - 2031
6.5.1.19. Southeast Asia Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2019 - 2031
6.5.1.20. Southeast Asia Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
6.5.1.21. Rest of Asia Pacific Oncology Drugs Market by Drug Class, Value (US$ Bn), 2019 - 2031
6.5.1.22. Rest of Asia Pacific Oncology Drugs Market by Indication, Value (US$ Bn), 2019 - 2031
6.5.1.23. Rest of Asia Pacific Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2019 - 2031
6.5.1.24. Rest of Asia Pacific Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
6.5.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Oncology Drugs Market Outlook, 2019 - 2031
7.1. Latin America Oncology Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2019 - 2031
7.1.1. Key Highlights
7.1.1.1. Chemotherapy
7.1.1.1.1. Alkylating Agents
7.1.1.1.2. Antimetabolites
7.1.1.1.3. Anti-tumour Antibiotics
7.1.1.1.4. Topoisomerase Inhibitors
7.1.1.1.5. Mitotic Inhibitors
7.1.1.1.6. Others
7.1.1.2. Targeted Therapy
7.1.1.2.1. Monoclonal Antibodies
7.1.1.2.2. Small molecule Inhibitors
7.1.1.3. Immunotherapy
7.1.1.3.1. Immune Checkpoint Inhibitors.
7.1.1.3.2. Cell Therapy and Gene Therapy
7.1.1.3.3. Oncolytic Virus Therapy
7.1.1.3.4. Immune System Modulators
7.1.1.3.5. Others
7.1.1.4. Hormonal Therapy
7.2. Latin America Oncology Drugs Market Outlook, by Indication, Value (US$ Bn), 2019 - 2031
7.2.1. Key Highlights
7.2.1.1. Breast Cancer
7.2.1.2. Lung Cancer
7.2.1.3. Prostate Cancer
7.2.1.4. Multiple Myeloma
7.2.1.5. Colorectal Cancer
7.2.1.6. Non-Hodgkin's Lymphoma
7.2.1.7. Kidney Cancer
7.2.1.8. Chronic lymphocytic Leukaemia
7.2.1.9. Melanoma
7.2.1.10. Others
7.3. Latin America Oncology Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2019 - 2031
7.3.1. Key Highlights
7.3.1.1. Oral
7.3.1.2. Injectable
7.4. Latin America Oncology Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2031
7.4.1. Key Highlights
7.4.1.1. Hospital Pharmacies
7.4.1.2. Retail Pharmacies
7.4.1.3. Others
7.4.2. BPS Analysis/Market Attractiveness Analysis
7.5. Latin America Oncology Drugs Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
7.5.1. Key Highlights
7.5.1.1. Brazil Oncology Drugs Market by Drug Class, Value (US$ Bn), 2019 - 2031
7.5.1.2. Brazil Oncology Drugs Market by Indication, Value (US$ Bn), 2019 - 2031
7.5.1.3. Brazil Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2019 - 2031
7.5.1.4. Brazil Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
7.5.1.5. Mexico Oncology Drugs Market by Drug Class, Value (US$ Bn), 2019 - 2031
7.5.1.6. Mexico Oncology Drugs Market by Indication, Value (US$ Bn), 2019 - 2031
7.5.1.7. Mexico Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2019 - 2031
7.5.1.8. Mexico Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
7.5.1.9. Argentina Oncology Drugs Market by Drug Class, Value (US$ Bn), 2019 - 2031
7.5.1.10. Argentina Oncology Drugs Market by Indication, Value (US$ Bn), 2019 - 2031
7.5.1.11. Argentina Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2019 - 2031
7.5.1.12. Argentina Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
7.5.1.13. Rest of Latin America Oncology Drugs Market by Drug Class, Value (US$ Bn), 2019 - 2031
7.5.1.14. Rest of Latin America Oncology Drugs Market by Indication, Value (US$ Bn), 2019 - 2031
7.5.1.15. Rest of Latin America Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2019 - 2031
7.5.1.16. Rest of Latin America Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
7.5.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Oncology Drugs Market Outlook, 2019 - 2031
8.1. Middle East & Africa Oncology Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2019 - 2031
8.1.1. Key Highlights
8.1.1.1. Chemotherapy
8.1.1.1.1. Alkylating Agents
8.1.1.1.2. Antimetabolites
8.1.1.1.3. Anti-tumour Antibiotics
8.1.1.1.4. Topoisomerase Inhibitors
8.1.1.1.5. Mitotic Inhibitors
8.1.1.1.6. Others
8.1.1.2. Targeted Therapy
8.1.1.2.1. Monoclonal Antibodies
8.1.1.2.2. Small molecule Inhibitors
8.1.1.3. Immunotherapy
8.1.1.3.1. Immune Checkpoint Inhibitors.
8.1.1.3.2. Cell Therapy and Gene Therapy
8.1.1.3.3. Oncolytic Virus Therapy
8.1.1.3.4. Immune System Modulators
8.1.1.3.5. Others
8.1.1.4. Hormonal Therapy
8.2. Middle East & Africa Oncology Drugs Market Outlook, by Indication, Value (US$ Bn), 2019 - 2031
8.2.1. Key Highlights
8.2.1.1. Breast Cancer
8.2.1.2. Lung Cancer
8.2.1.3. Prostate Cancer
8.2.1.4. Multiple Myeloma
8.2.1.5. Colorectal Cancer
8.2.1.6. Non-Hodgkin's Lymphoma
8.2.1.7. Kidney Cancer
8.2.1.8. Chronic lymphocytic Leukaemia
8.2.1.9. Melanoma
8.2.1.10. Others
8.3. Middle East & Africa Oncology Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2019 - 2031
8.3.1. Key Highlights
8.3.1.1. Oral
8.3.1.2. Injectable
8.4. Middle East & Africa Oncology Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2031
8.4.1. Key Highlights
8.4.1.1. Hospital Pharmacies
8.4.1.2. Retail Pharmacies
8.4.1.3. Others
8.4.2. BPS Analysis/Market Attractiveness Analysis
8.5. Middle East & Africa Oncology Drugs Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
8.5.1. Key Highlights
8.5.1.1. GCC Oncology Drugs Market by Drug Class, Value (US$ Bn), 2019 - 2031
8.5.1.2. GCC Oncology Drugs Market by Indication, Value (US$ Bn), 2019 - 2031
8.5.1.3. GCC Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2019 - 2031
8.5.1.4. GCC Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
8.5.1.5. South Africa Oncology Drugs Market by Drug Class, Value (US$ Bn), 2019 - 2031
8.5.1.6. South Africa Oncology Drugs Market by Indication, Value (US$ Bn), 2019 - 2031
8.5.1.7. South Africa Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2019 - 2031
8.5.1.8. South Africa Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
8.5.1.9. Egypt Oncology Drugs Market by Drug Class, Value (US$ Bn), 2019 - 2031
8.5.1.10. Egypt Oncology Drugs Market by Indication, Value (US$ Bn), 2019 - 2031
8.5.1.11. Egypt Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2019 - 2031
8.5.1.12. Egypt Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
8.5.1.13. Nigeria Oncology Drugs Market by Drug Class, Value (US$ Bn), 2019 - 2031
8.5.1.14. Nigeria Oncology Drugs Market by Indication, Value (US$ Bn), 2019 - 2031
8.5.1.15. Nigeria Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2019 - 2031
8.5.1.16. Nigeria Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
8.5.1.17. Rest of Middle East & Africa Oncology Drugs Market by Drug Class, Value (US$ Bn), 2019 - 2031
8.5.1.18. Rest of Middle East & Africa Oncology Drugs Market by Indication, Value (US$ Bn), 2019 - 2031
8.5.1.19. Rest of Middle East & Africa Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2019 - 2031
8.5.1.20. Rest of Middle East & Africa Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
8.5.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Company Market Share Analysis, 2023
9.2. Competitive Dashboard
9.3. Company Profiles
9.3.1. GlaxoSmithKline
9.3.1.1. Company Overview
9.3.1.2. Product Portfolio
9.3.1.3. Financial Overview0020
9.3.1.4. Business Strategies and Development
9.3.2. AstraZeneca plc
9.3.2.1. Company Overview
9.3.2.2. Product Portfolio
9.3.2.3. Financial Overview
9.3.2.4. Business Strategies and Development
9.3.3. AbbVie
9.3.3.1. Company Overview
9.3.3.2. Product Portfolio
9.3.3.3. Financial Overview
9.3.3.4. Business Strategies and Development
9.3.4. Pfizer Inc.
9.3.4.1. Company Overview
9.3.4.2. Product Portfolio
9.3.4.3. Financial Overview
9.3.4.4. Business Strategies and Development
9.3.5. Amgen Inc.
9.3.5.1. Company Overview
9.3.5.2. Product Portfolio
9.3.5.3. Financial Overview
9.3.5.4. Business Strategies and Development
9.3.6. Gilead Sciences, Inc.
9.3.6.1. Company Overview
9.3.6.2. Product Portfolio
9.3.6.3. Financial Overview
9.3.6.4. Business Strategies and Development
9.3.7. F. Hoffmann-La Roche Ltd
9.3.7.1. Company Overview
9.3.7.2. Product Portfolio
9.3.7.3. Financial Overview
9.3.7.4. Business Strategies and Development
9.3.8. Bristol-Myers Squibb Company (Celgene Corp)
9.3.8.1. Company Overview
9.3.8.2. Product Portfolio
9.3.8.3. Financial Overview
9.3.8.4. Business Strategies and Development
9.3.9. Novartis AG
9.3.9.1. Company Overview
9.3.9.2. Product Portfolio
9.3.9.3. Financial Overview
9.3.9.4. Business Strategies and Development
9.3.10. Johnson & Johnson
9.3.10.1. Company Overview
9.3.10.2. Product Portfolio
9.3.10.3. Financial Overview
9.3.10.4. Business Strategies and Development
9.3.11. Merck & Co.
9.3.11.1. Company Overview
9.3.11.2. Product Portfolio
9.3.11.3. Financial Overview
9.3.11.4. Business Strategies and Development
9.3.12. Eli Lilly and Company
9.3.12.1. Company Overview
9.3.12.2. Product Portfolio
9.3.12.3. Financial Overview
9.3.12.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations